about
Long-term effects of calorie restriction on serum sex-hormone concentrations in menPneumonia, thrombosis and vascular diseaseNOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery diseaseIs NOX2 upregulation implicated in myocardial injury in patients with pneumonia?Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin.Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia.Platelet isoprostane overproduction in diabetic patients treated with aspirin.Vitamin E for the treatment of cardiovascular disease: is there a future?Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes: Results From a Prospective Cohort Study.Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis.Relationship between platelet and urinary 8-Iso-PGF2α levels in subjects with different degrees of NOX2 regulationModerate weight loss decreases oxidative stress and increases antioxidant status in patients with metabolic syndrome.Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.Low-grade endotoxemia and clotting activation in the early phase of pneumonia.Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events.Platelet activation is associated with myocardial infarction in patients with pneumonia.Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia.Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia.Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.Endotoxemia as a trigger of thrombosis in cirrhosis.Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.Adenovirus 36 DNA in human adipose tissue.Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects.Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation.Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia.Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation.Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure.Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure.Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E.Fibrinogen as predictor of ischemic stroke in patients with non-valvular atrial fibrillation.Hospitalization for pneumonia and risk of cardiovascular disease.Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation.Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation.Reply to: “Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke”Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?
P50
Q24623081-972C96F4-2A80-43C9-835B-5C555CF35D35Q26853685-E6C66B98-86F1-4746-8C8F-218299F8F972Q28259845-E3369FF6-816A-41C9-BB12-D4089692D0ADQ33687757-29E79625-792D-465B-953E-9C84A8C84E08Q35088200-A47627E1-1D48-4989-A42C-BC4CBF6DF49AQ35362847-175D9B22-8BA7-4082-8559-09612A7A20EBQ35976574-7B17C96E-BF64-446B-91A0-7863C494D69AQ36064433-14B32653-574A-4E9F-B2D9-6D6F0F6B716AQ36566789-555EB269-8F02-40A6-9A59-32F04F4E8C23Q36751392-0322FFC5-DA0C-4596-B999-B61CAFC4D8C1Q36974316-ACDD2D87-DFD8-4FA9-88ED-C69BCAD0AFA2Q37556294-751B1C72-FBB5-4795-A98E-7D43E779A4A8Q38471149-340D545E-1C45-404F-972C-6C14DF5D8797Q38930881-8122875A-2647-41E1-A9FA-E0AB7E82D85CQ38930892-52090E0E-2EAE-41BD-9AFD-0EB371C522FEQ38930897-41888CFE-83AF-476B-B9F3-95FF12134CBCQ39187283-E4B87ADC-0F14-48B8-B71A-D340E0EBD287Q39562368-028BC0A8-55A3-44D8-8A11-F0B9845A0166Q40595356-DAA540F8-079C-49F4-A6EF-8F1CDAA626F4Q40733548-85FB44F5-A74E-440F-BCB1-0AD0351BDFE3Q40917241-1FB76EB3-C676-4D62-9F10-DC5F741A97C7Q40950038-5D8C2872-5E7D-4EC6-83F7-77D5887122A9Q40992076-83F80F17-D626-4D7B-9333-8189CB770883Q41041135-EFEDA0A0-0492-4496-A98C-3DD5119D7A0BQ41099825-14FD58F5-A2A6-4E6E-BD68-666AA52E1A12Q41626846-C81621D3-FDE1-47F1-9D5A-6420416F3557Q41645877-856908A7-5E54-414F-A597-71B353A6EA10Q42881426-9AD3F5FB-A85A-47FD-871C-10A96CB4DD5DQ43228814-58435546-FF81-4A5E-BC73-8E3D94EFE139Q46249421-F5874F11-84B8-488A-A884-5711DEF5C992Q46547146-162037A8-75E4-4C2E-AF33-8FA825D4EB92Q46748420-F4B90EAE-D8CD-418D-9974-38DECBF8E291Q46861532-2D38696F-64AB-4E5E-808E-B50EE4139CBCQ48139161-E369576F-40E1-4CD4-8B3D-74638FFE3EBAQ51634101-6D70154F-6FDD-44A5-8ADD-152CABB94877Q51813174-D58895B7-2058-4161-8557-518B0E376D20Q52631792-C6C04EEE-5EE2-41D9-A7E1-12BBA93A7F68Q54335399-7C64A188-F750-4971-82F5-5DBE51C9A9E1Q58420630-4A7BE7D9-E806-44DA-9874-351733491577Q58420659-81A549BD-8B05-4A2B-A4B5-E9A82AD99A4C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Cangemi
@ast
Roberto Cangemi
@en
Roberto Cangemi
@es
Roberto Cangemi
@nl
Roberto Cangemi
@sl
type
label
Roberto Cangemi
@ast
Roberto Cangemi
@en
Roberto Cangemi
@es
Roberto Cangemi
@nl
Roberto Cangemi
@sl
prefLabel
Roberto Cangemi
@ast
Roberto Cangemi
@en
Roberto Cangemi
@es
Roberto Cangemi
@nl
Roberto Cangemi
@sl
P106
P1153
6602899071
P21
P31
P496
0000-0002-4097-2061